Comparison of an increased dosage regimen of rabeprazole versus a concomitant dosage regimen of famotidine with rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotypes

Clinical Pharmacology and Therapeutics

Volumn 77, Issue 4, 2005, Pages 302-311

  Sugimoto, Mitsushige ^a   Furuta, Takahisa ^b   Shirai, Naohito ^b   Nakamura, Akiko ^b   Kajimura, Masayoshi ^b   Hishida, Akira ^b   Ohashi, Kyoichi ^b   Ishizaki, Takashi ^b  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; FAMOTIDINE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; GENOTYPE; HELICOBACTER PYLORI; HUMAN; MONITORING; NORMAL HUMAN; PH MEASUREMENT; PRIORITY JOURNAL; STOMACH ACID;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADENOSINE TRIPHOSPHATASES; ADULT; ARYL HYDROCARBON HYDROXYLASES; BENZIMIDAZOLES; CIRCADIAN RHYTHM; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FAMOTIDINE; FEMALE; GASTRIC ACID; GENOTYPE; HISTAMINE H2 ANTAGONISTS; HUMANS; MALE; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; POLYMORPHISM, GENETIC; PROTON-TRANSLOCATING ATPASES;

EID: 16344380664     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2004.10.010     Document Type: Article

References (42)

1. E.C. Klinkenberg-Knol, H.P. Festen, J.B. Jansen, C.B. Lamers, F. Nelis, P. Snel Long-term treatment with omeprazole for refractory reflux esophagitis efficacy and safety Ann Intern Med 121 1994 161 167
2. J.G. Hatlebakk, P.O. Katz, D.O. Castell Medical therapy. Management of the refractory patient Gastroenterol Clin North Am 28 1999 847 860
3. N.J. Bell, D. Burget, C.W. Howden, J. Wilkinson, R.H. Hunt Appropriate acid suppression for the management of gastro-oesophageal reflux disease Digestion 51 Suppl 1 1992 59 67
4. R.H. Hunt Importance of pH control in the management of GERD Arch Intern Med 159 1999 649 657
5. P.L. Peghini, P.O. Katz, N.A. Bracy, D.O. Castell Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors Am J Gastroenterol 93 1998 763 767
6. T. Ishizaki, Y. Horai Review article cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole Aliment Pharmacol Ther 13 Suppl 3 1999 27 36
7. S. Yasuda, Y. Horai, Y. Tomono, H. Nakai, C. Yamato, K. Manabe Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4′-hydroxylation status Clin Pharmacol Ther 58 1995 143 154
8. T. Andersson Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole Clin Pharmacokinet 31 1996 9 28
9. N. Shirai, T. Furuta, Y. Moriyama, H. Okochi, K. Kobayashi, M. Takashima Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH Aliment Pharmacol Ther 15 2001 1929 1937
10. Y. Horai, M. Kimura, H. Furuie, K. Matsuguma, S. Irie, Y. Koga Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes Aliment Pharmacol Ther 15 2001 793 803
11. I. Ieiri, Y. Kishimoto, H. Okochi, K. Momiyama, T. Morita, M. Kitano Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism Eur J Clin Pharmacol 57 2001 485 492
12. N. Shirai, T. Furuta, F. Xiao, M. Kajimura, H. Hanai, K. Ohashi Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night-time in different CYP2C19 genotype groups Aliment Pharmacol Ther 16 2002 837 846
13. M. Sugimoto, T. Furuta, N. Shirai, M. Kajimura, A. Hishida, M. Sakurai Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status Clin Pharmacol Ther 76 2004 290 301
14. T. Shimatani, M. Inoue, T. Kuroiwa, Y. Horikawa Rabeprazole 10 mg twice daily is superior to 20 mg once daily for night-time gastric acid suppression Aliment Pharmacol Ther 19 2004 113 122
15. J.G. Hatlebakk, P.O. Katz, B. Kuo, D.O. Castell Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily Aliment Pharmacol Ther 12 1998 1235 1240
16. J. Hammer, B. Schmidt Effect of splitting the dose of esomeprazole on gastric acidity and nocturnal acid breakthrough Aliment Pharmacol Ther 19 2004 1105 1110
17. T. Furuta, N. Shirai, F. Xiao, K. Ohashi, T. Ishizaki Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19 Clin Pharmacol Ther 70 2001 484 492
18. T. Furuta, N. Shirai, M. Takashima, F. Xiao, H. Hanai, K. Nakagawa Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin Pharmacogenetics 11 2001 341 348
19. T. Furuta, N. Shirai, K. Ohashi, T. Ishizaki Therapeutic impact of CYP2C19 pharmacogenetics on proton pump inhibitor-based eradication therapy for Helicobacter pylori Methods Find Exp Clin Pharmacol 25 2003 131 143
20. P.L. Peghini, P.O. Katz, D.O. Castell Ranitidine controls nocturnal gastric acid breakthrough on omeprazole a controlled study in normal subjects Gastroenterology 115 1998 1335 1339
21. T. Katsube, K. Adachi, A. Kawamura, K. Amano, Y. Uchida, M. Watanabe Helicobacter pylori infection influences nocturnal gastric acid breakthrough Aliment Pharmacol Ther 14 2000 1049 1056
22. S. Xue, P.O. Katz, P. Banerjee, R. Tutuian, D.O. Castell Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors Aliment Pharmacol Ther 15 2001 1351 1356
23. L.J. Hixson, C.L. Kelley, W.N. Jones, C.D. Tuohy Current trends in the pharmacotherapy for peptic ulcer disease Arch Intern Med 152 1992 726 732
24. G. Sachs, J.M. Shin, C. Briving, B. Wallmark, S. Hersey The pharmacology of the gastric acid pump the H+,K+ ATPase Annu Rev Pharmacol Toxicol 35 1995 277 305
25. U. Gladziwa, U. Koltz Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure Clin Pharmacokinet 27 1994 393 408
26. S.M. de Morais, G.R. Wilkinson, J. Blaisdell, U.A. Meyer, K. Nakamura, J.A. Goldstein Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese Mol Pharmacol 46 1994 594 598
27. S.M. de Morais, G.R. Wilkinson, J. Blaisdell, K. Nakamura, U.A. Meyer, J.A. Goldstein The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans J Biol Chem 269 1994 15419 15422
28. T. Kubota, K. Chiba, T. Ishizaki Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population Clin Pharmacol Ther 60 1996 661 666
29. T. Furuta, N. Shirai, F. Watanabe, S. Honda, K. Takeuchi, T. Iida Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole Clin Pharmacol Ther 72 2002 453 460
30. M.M. Wolfe, A.H. Soll The physiology of gastric acid secretion N Engl J Med 319 1988 1707 1715
31. G. Sachs, J.M. Shin, K. Munson, O. Vagin, N. Lambrecht, D.R. Scott Review article the control of gastric acid and Helicobacter pylori eradication Aliment Pharmacol Ther 14 2000 1383 1401
32. J.G. Moore, M. Wolfe The relation of plasma gastrin to the circadian rhythm of gastric acid secretion in man Digestion 9 1973 97 105
33. K. Adachi, H. Fujishiro, T. Katsube, M. Yuki, M. Ono, A. Kawamura Predominant nocturnal acid reflux in patients with Los Angeles grade C and D reflux esophagitis J Gastroenterol Hepatol 16 2001 1191 1196
34. A. Tari, G. Yamamoto, K. Sumii, M. Sumii, Y. Takehara, K. Haruma Role of histamine2 receptor in increased expression of rat gastric H(+)-K(+)-ATPase alpha-subunit induced by omeprazole Am J Physiol 265 1993 G752 G758
35. H.G. Xie, C.M. Stein, R.B. Kim, G.R. Wilkinson, D.A. Flockhart, A.J. Wood Allelic, genotypic and phenotypic distributions of S-mephenytoin 4′-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world Pharmacogenetics 9 1999 539 549
36. H.K. Roh, M.L. Dahl, G. Tybring, H. Yamada, Y.N. Cha, L. Bertilsson CYP2C19 genotype and phenotype determined by omeprazole in a Korean population Pharmacogenetics 6 1996 547 551
37. W.K. Fackler, T.M. Ours, M.F. Vaezi, J.E. Richter Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough Gastroenterology 122 2002 625 632
38. Y. Komazawa, K. Adachi, T. Mihara, M. Ono, A. Kawamura, H. Fujishiro Tolerance to famotidine and ranitidine treatment after 14 days of administration in healthy subjects without Helicobacter pylori infection J Gastroenterol Hepatol 18 2003 678 682
39. K. Adachi, Y. Komazawa, H. Fujishiro, T. Mihara, M. Ono, M. Yuki Nocturnal gastric acid breakthrough during the administration of rabeprazole and ranitidine in Helicobacter pylori-negative subjects effects of different regimens J Gastroenterol 38 2003 830 835
40. P. Netzer, C. Gaia, M. Sandoz, T. Huluk, A. Gut, F. Halter Effect of repeated injection and continuous infusion of omeprazole and ranitidine on intragastric pH over 72 hours Am J Gastroenterol 94 1999 351 357
41. L. Lachman, C.W. Howden Twenty-four-hour intragastric pH tolerance within 5 days of continuous ranitidine administration Am J Gastroenterol 95 2000 57 61
42. A.K. Sandvik, E. Brenna, H.L. Waldum Review article the pharmacological inhibition of gastric acid secretion--tolerance and rebound Aliment Pharmacol Ther 11 1997 1013 1018